Literature DB >> 12454814

Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation.

Gamze Ayata1, Fredric D Gordon, W David Lewis, Elizabeth Pomfret, James J Pomposelli, Roger L Jenkins, Urmila Khettry.   

Abstract

The incidence of cryptogenic cirrhosis (CC) has decreased since the discovery of hepatitis C virus (HCV), still the etiology in 5% of cases with cirrhosis remains unresolved. Our aims were to define the clinicopathologic features of CC at liver transplantation (LT), evaluate the post-LT course with outcome and define the possible pathogenetic mechanisms. 27/534 LT recipients (5%) over a period of 16.5 years were entered in the LT database as cases of CC. A detailed analysis of pre- and post-LT clinical and all liver pathology specimens was performed. Based on clinicopathologic findings, a more definite diagnosis was possible in 23 of 27 (85%): Nonalcoholic steatohepatitis (NASH) in 9 (33%), autoimmune liver disease (AILD) in 6 (22%), alcoholic liver disease in 4, secondary biliary cirrhosis in 2 and 1 each of hepatitis C and portal venopathy. 4/27 cases remained unresolved. In the NASH group, native livers had focal steatosis, Mallory's hyalin, glycogenated hepatocytic nuclei, high-grade inflammation, and 3+ bile duct proliferation. Large cell dysplasia was more common in this group compared to other patients. Two patients had recurrence of NASH after LT. In AILD group native livers had little or no bile duct proliferation. Two patients had recurrence in AILD group. Of 27 patients 19 are alive (70%) with a follow-up of 407-3647 days. Based on the study results, the following conclusions were reached: (1) CC results from varying etiologies, which can be defined by a careful clinicopathologic analysis in a majority (85%) of cases; (2) Nonalcoholic steatohepatitis (33%) and AILD (22%) are the common underlying causes of CC; and (3) Post-LT outcome for CC is disease dependent with, recurrent disease seen in both nonalcoholic steatohepatitis (22%) and autoimmune liver disease (33%). Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12454814     DOI: 10.1053/hupa.2002.129419

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

1.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

Review 2.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 3.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

4.  Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation.

Authors:  Karim Samara; Chen Liu; Consuelo Soldevila-Pico; David R Nelson; Manal F Abdelmalek
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

5.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

Review 6.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

7.  Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.

Authors:  Jacqueline G O'Leary; Carmen Landaverde; Linda Jennings; Robert M Goldstein; Gary L Davis
Journal:  Clin Gastroenterol Hepatol       Date:  2011-04-15       Impact factor: 11.382

8.  Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients.

Authors:  Sanjiv Saigal; Nabeen C Nayak; Deepali Jain; Vinay Kumaran; Ravi Mohanka; Neeraj Saraf; Amit Rastogi; Naimesh Mehta; Samiran Nundy; Arvinder Soin
Journal:  Hepatol Int       Date:  2011-01-12       Impact factor: 6.047

Review 9.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

Review 10.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.